Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain clock may play role in diabetes risk

NCT ID NCT05314855

Knowledge-focused Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at whether the brain's central clock (the suprachiasmatic nucleus) works differently in people with insulin resistance or type 2 diabetes. Researchers used advanced MRI scans to measure brain activity over 24 hours in 28 obese adults with varying insulin sensitivity. The goal was to understand how the brain clock might be involved in the development of insulin resistance.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help explain how the brain's internal clock affects insulin resistance and type 2 diabetes, pointing toward new treatment targets.
What could go wrong
This is a small observational study (28 people) that only measures brain activity, not a treatment. It may not lead to any direct medical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

28 people

The number who actually took part.

Started

Jan 2023

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Primary care clinics, community sample

Ages

25 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Group 1: obese people with normal insulin sensitivity * age 25-65 years * BMI\>30 * fasting plasma insulin ≤62 pmol/L * fasting plasma glucose \<5.6 mmol/L * Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) ≤ 4.5 Group 2: obese people with insulin resistance * age 25-65 years * BMI\>30 * fasting plasma insulin \>62 pmol/L * not fulfilling the American Diabetes Association (ADA) criteria for type 2 DM Group 3: obese subjects with overt type 2 DM * age 25-65 years * BMI\>30 * diagnosis type 2 DM according to ADA criteria Exclusion Criteria: * An extreme chronotype (midpoint of sleep on free days (MSFsc) before 2:00 or after 6:00). * Active psychiatric disorder (including circadian rhythm sleep disorder) as defined in Diagnostic and Statistical Manual of Mental Disorders (DSM) 5 * Disorders of the central nervous system (Early-onset dementia, stroke, epilepsy, Parkinson's disease, brain tumor) * Severe visual impairment (WHO classification) * Shift workers * Crossing \> 2 time zones in the 3 months before the study * Patients with type 2 DM receiving insulin treatment or glucagon-like peptide (GLP) 1 agonists * MRI contraindications

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Insulin resistance are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Insulin Resistance type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Insulin resistance Type 2 diabetes

Contacts and locations

Locations

  • Amsterdam University Medical Centers, location AMC

    Amsterdam, North Holland, 1105AZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.